가격 및 재고 정보를 현재 이용할 수 없음 고객지원팀으로 연락바랍니다.
추천 제품
사용
sufficient for 25 reactions
제조업체/상표
Cytiva 25-6600-22
재고 정보
not available in Japan
배송 상태
dry ice
저장 온도
−70°C
관련 카테고리
일반 설명
illustra™ GenomiPhi™ HY DNA Amplification Kit offers highly efficient and representative whole-genome amplification with 40 to 50 μg yield from nanogram amounts of DNA sample.
The illustra™ GenomiPhi™ HY DNA Amplification Kit is part of the Phi29 DNA polymerase family of products from Cytiva. It contains all of the components necessary for midi-scale whole genome amplification by isothermal strand displacement amplification.
Amplification is highly uniform over the entire genome so that locus representation remains extremely close to the original DNA sample. Furthermore, amplification is carried out with very high fidelity due to Phi29 DNA polymerase proofreading activity.
The illustra™ GenomiPhi™ HY DNA Amplification Kit procedure is quick, simple and does not require a thermal cycler. A typical DNA yield of 40 to 50 μg DNA can be achieved in four h with little hands-on time. The average product length is over 10 kb. The starting material for GenomiPhi™ reactions can be purified DNA from any commercial kit or homebrew method, or a nonpurified cell lysate may be used. The kit was verified with DNA from various clinical samples including blood and buccal swabs.
GenomiPhi™ amplified DNA is suitable for various applications such as genotyping (SNP, STR, array CGH), cloning, sequencing, and DNA archiving.
The illustra™ GenomiPhi™ HY DNA Amplification Kit is part of the Phi29 DNA polymerase family of products from Cytiva. It contains all of the components necessary for midi-scale whole genome amplification by isothermal strand displacement amplification.
Amplification is highly uniform over the entire genome so that locus representation remains extremely close to the original DNA sample. Furthermore, amplification is carried out with very high fidelity due to Phi29 DNA polymerase proofreading activity.
The illustra™ GenomiPhi™ HY DNA Amplification Kit procedure is quick, simple and does not require a thermal cycler. A typical DNA yield of 40 to 50 μg DNA can be achieved in four h with little hands-on time. The average product length is over 10 kb. The starting material for GenomiPhi™ reactions can be purified DNA from any commercial kit or homebrew method, or a nonpurified cell lysate may be used. The kit was verified with DNA from various clinical samples including blood and buccal swabs.
GenomiPhi™ amplified DNA is suitable for various applications such as genotyping (SNP, STR, array CGH), cloning, sequencing, and DNA archiving.
애플리케이션
For midi-scale whole genome amplification by isothermal strand displacement amplification; typical downstream applications are genotyping (SNP, STR, array CGH) and DNA archiving.
특징 및 장점
- Yields high-quality DNA (e.g., for high-throughput genotyping, hybridization, and DNA archival).
- Outperforms PCR-based whole genome amplification techniques.
- Quick and simple automation-friendly protocol; no thermal cycler required.
- No template-independent, background amplification product.
- Representative isothermal amplification of the whole genome.
저장 및 안정성
Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.
분석 메모
To view the Certificate of Analysis for this product, please visit www.cytiva.com.
법적 정보
GenomiPhi
On packaging and insert:
For use only as licensed by Qiagen GmbH. and Cytiva. The Phi 29 DNA polymerase may not be re-sold or used except in conjunction with the other components of this kit. See US patent numbers 5,854,033, 6,124,120, 6,143,495, 6,323,009, 5,576,204, and equivalent patents and patent applications in other countries.
On container:
Subject to proprietary rights of Cytiva. May not be re-sold or used except with the other components of this kit. See US patent numbers 5,576,204, and equivalent patents and patent applications in other countries.
On packaging and insert:
For use only as licensed by Qiagen GmbH. and Cytiva. The Phi 29 DNA polymerase may not be re-sold or used except in conjunction with the other components of this kit. See US patent numbers 5,854,033, 6,124,120, 6,143,495, 6,323,009, 5,576,204, and equivalent patents and patent applications in other countries.
On container:
Subject to proprietary rights of Cytiva. May not be re-sold or used except with the other components of this kit. See US patent numbers 5,576,204, and equivalent patents and patent applications in other countries.
GenomiPhi is a trademark of Cytiva
illustra is a trademark of Cytiva
Storage Class Code
12 - Non Combustible Liquids
가장 최신 버전 중 하나를 선택하세요:
Jennifer Yen et al.
Genome biology, 14(10), R113-R113 (2013-10-24)
Melanoma is the most deadly form of skin cancer. Expression of oncogenic BRAF or NRAS, which are frequently mutated in human melanomas, promote the formation of nevi but are not sufficient for tumorigenesis. Even with germline mutated p53, these engineered
Enrico Tiacci et al.
Haematologica, 98(4), 635-639 (2013-01-26)
The BRAF-V600E mutation defines genetically hairy cell leukemia among B-cell leukemias and lymphomas. In solid tumors, BRAF-V600E is known to aberrantly activate the oncogenic MEK-ERK pathway, and targeted BRAF and/or MEK inhibitors have shown remarkable efficacy in clinical trials in
Jeffrey S McLean et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(26), E2390-E2399 (2013-06-12)
The "dark matter of life" describes microbes and even entire divisions of bacterial phyla that have evaded cultivation and have yet to be sequenced. We present a genome from the globally distributed but elusive candidate phylum TM6 and uncover its
A E Van't Hof et al.
Heredity, 110(3), 283-295 (2012-12-06)
We have constructed a linkage map for the peppered moth (Biston betularia), the classical ecological genetics model of industrial melanism, aimed both at localizing the network of loci controlling melanism and making inferences about chromosome dynamics. The linkage map, which
E Ramos et al.
The pharmacogenomics journal, 14(3), 217-222 (2013-07-10)
Pharmacogenomically relevant markers of drug response and adverse drug reactions are known to vary in frequency across populations. We examined minor allele frequencies (MAFs), genetic diversity (FST) and population structure of 1156 genetic variants (including 42 clinically actionable variants) in
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
